Recent work by Xie et al. demonstrated that elevated AXL expression in TKI-resistant murine HCC models induces an immunosuppressive microenvironment, reducing the efficacy of anti-PD1 therapy, and was reversed by combining BGB324 with sorafenib and anti-PD1 therapy [54]. Here, AXL is linked to hepatocellular carcinoma.